Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Gains from Investment Securities: 2014-2024

Historic Gains from Investment Securities for Editas Medicine (EDIT) over the last 11 years, with Dec 2024 value amounting to -$3.4 million.

  • Editas Medicine's Gains from Investment Securities fell 1012.38% to -$1.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$6.4 million, marking a year-over-year decrease of 253.86%. This contributed to the annual value of -$3.4 million for FY2024, which is 200.93% down from last year.
  • As of FY2024, Editas Medicine's Gains from Investment Securities stood at -$3.4 million, which was down 200.93% from $3.3 million recorded in FY2023.
  • In the past 5 years, Editas Medicine's Gains from Investment Securities registered a high of $24.5 million during FY2022, and its lowest value of -$3.4 million during FY2024.
  • In the last 3 years, Editas Medicine's Gains from Investment Securities had a median value of $3.3 million in 2023 and averaged $8.2 million.
  • In the last 5 years, Editas Medicine's Gains from Investment Securities surged by 1,393.18% in 2021 and then slumped by 200.93% in 2024.
  • Editas Medicine's Gains from Investment Securities (Yearly) stood at $719,000 in 2020, then soared by 1,393.18% to $10.7 million in 2021, then soared by 128.62% to $24.5 million in 2022, then crashed by 86.41% to $3.3 million in 2023, then crashed by 200.93% to -$3.4 million in 2024.